First Ophthalmic Bevacizumab Approved
Outlook Therapeutics Secures FDA Approval for LYTENAVA, First Eye-Specific Wet AMD Treatment.
Anonymous
Key Points
1
FDA issued three CRLs for Outlook Therapeutics' BLA before approval: the first CRL in August 2023 citing Chemistry, Manufacturing, and Controls (CMC) issues, open observations from manufacturing inspections, and a lack of substantial evidence; the second CRL in August 2025 citing lack of substantial evidence of effectiveness and the need for more confirmatory efficacy data; and a third CRL on December 31, 2025 stating that the additional data did not change the conclusion that confirmatory efficacy data were needed.
2
Outlook Therapeutics pursued Formal Dispute Resolution with the FDA's Office of New Drugs, and the agency granted an appeal after the FDR process, enabling the BLA to proceed; the company first submitted the BLA in March 2022.
3
LYTENAVA is bevacizumab-vikg (bevazumab gamma), the ophthalmic bevacizumab developed specifically for the eye, with FDA approval for ONS-5010/LYTENAVA and emphasis on the product having approved labeling, validated manufacturing, and ongoing FDA regulatory oversight.
4
Bevacizumab already accounts for the majority of first-line anti-VEGF therapy in retina care, a context that underscores the potential impact of an FDA-approved ophthalmic bevacizumab option like LYTENAVA on treatment patterns.
The FDA has approved LYTENAVA (bevacizumab-vikg) for wet age-related macular degeneration, making it the first and only FDA-approved ophthalmic bevacizumab formulation built specifically for the eye, according to MarketScreener. The approval ends a years-long regulatory battle for Outlook Therapeutics, which first filed its application in March 2022.
CEO Bob Jahr called the milestone defining for both physicians and patients. LYTENAVA now comes with approved labeling, validated manufacturing, and ongoing FDA oversight — something no other bevacizumab eye treatment has had before, GuruFocus reported.
Three Rejections and a Formal Appeal Before Approval
The road to approval was unusually rocky. The FDA issued three complete response letters, or CRLs, before saying yes. The first came in August 2023, citing manufacturing problems and a lack of substantial evidence. A second CRL followed in August 2025, again questioning the drug's efficacy data. Then, on December 31, 2025, a third CRL landed, stating that new data still did not prove the drug worked well enough, according to MarketScreener.
Outlook Therapeutics did not give up. The company pursued Formal Dispute Resolution with the FDA's Office of New Drugs. The agency granted an appeal after that process, allowing the application to move forward. The approval that followed marked the end of one of the longer BLA battles in recent ophthalmic drug history.
What Makes LYTENAVA Different From Existing Bevacizumab Use
Bevacizumab is not new to eye doctors. It already accounts for the majority of first-line anti-VEGF treatments in retina care. Anti-VEGF drugs block a protein that causes abnormal blood vessel growth in the eye. But until now, doctors used an off-label version of bevacizumab — a cancer drug — repackaged for eye injections, Conexiant reported.
LYTENAVA is different. It was designed from the ground up for the eye. It has its own FDA-approved label, validated manufacturing, and regulatory oversight. That gives doctors and patients a formal, evidence-backed option for the first time, GuruFocus noted.
Exclusivity Period Could Shield LYTENAVA for 12 Years
Outlook Therapeutics says it expects 12 years of reference product exclusivity under the Biologics Price Competition and Innovation Act, according to MarketScreener. That law gives makers of biological drugs a long window before cheaper biosimilar versions can enter the market. It is a significant business advantage for a company that spent years and millions fighting for approval.
The company also announced plans to build out a full commercial franchise around LYTENAVA. With bevacizumab already dominant in retina clinics, a formalized FDA-approved version could shift treatment patterns quickly, The State reported.
A Potential New Standard for Wet AMD Treatment
Wet AMD causes abnormal blood vessels to grow under the retina, leaking fluid and damaging central vision. It is a leading cause of vision loss in older adults. Anti-VEGF injections are the main treatment, and bevacizumab has long been a cheap, widely used choice — just never an officially approved one for the eye, according to Tri-City Herald.
LYTENAVA's approval could now set a new baseline for what bevacizumab therapy looks like in the clinic. Physicians gain a drug with a clean regulatory record. Patients get a treatment built and tested specifically for their condition. CEO Jahr said the approval is defining — not just for Outlook, but for the entire field of retina care.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
95
Reach
108
A
AnonymousAuthor
